🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 61 of 151

  1. IL-1Ra Kineret®

    United Therapeutics Europe Ltd

    Intracerebral Haemorrhage

    phase 2 small molecule completed

    1 trial

  2. IL-6 aGVHD Siltuximab: A phase II study to assess the efficacy and tolerability of siltuximab plus corticosteroids in first line treatment of grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract.

    Disc Medicine

    Grade III/IV acute graft versus host disease of the liver of/and the gastro-intestinal tract

    phase 2 other active

    1 trial

  3. ILT-101 liquide, Placebo of ILT-101

    Pari Pharma GmbH

    Autism Spectrum disorder ASD

    phase 2 small molecule active

    1 trial

  4. ILT-101 liquide, Placebo of ILT-101, CICLOSPORIN

    Pari Pharma GmbH

    Patient with newly diagnosed (≤ 3 months) type 1 diabetes stage 3

    phase 2 small molecule active

    1 trial

  5. IMC-M113V

    Immunocore Ireland Limited

    Chronic HIV infection

    phase 2 small molecule active

    1 trial

  6. IMC-R117C

    Immunocore Ireland Limited

    Cancer

    phase 2 small molecule active

    1 trial

  7. IMCIVREE 10 mg/ml solution for injection

    Disc Medicine

    ROHHAD syndrome

    phase 2 small molecule active

    1 trial

  8. IMD-1041

    Lxo Ireland Designated Activity Company

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule active

    1 trial

  9. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Muscle-invasive bladder cancer

    phase 2 small molecule active

    1 trial

  10. IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Patients With Muscle-Invasive Bladder Cancer

    phase 2 small molecule active

    1 trial

  11. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Histologically confirmed frail Limited Disease Small Cell Lung Cancer (ECOG PS 2, ECOG PS 0-1 and older than 70 or did not receive a concomitant thoracic CRT because of comorbidities) previously untreated

    phase 2 small molecule active

    1 trial

  12. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Patients with metastatic breast cancer in 1st or 2nd line of chemotherapy

    phase 2 small molecule active

    1 trial

  13. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Patients with locally advanced or metastatic solid tumours

    phase 2 small molecule active

    1 trial

  14. IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  15. IMFINZI 50 mg/mL concentrate for solution for infusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    Non small cell lung cancer, Poor general status

    phase 2 small molecule active

    1 trial

  16. IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    unresectable stage III NSCLC (Non–small-cell lung cancer)

    phase 2 small molecule active

    1 trial

  17. IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIBIV)

    phase 2 small molecule active

    1 trial

  18. IMFINZI 50 mg/mL concentrate for solution for infusion.

    Fondazione Telethon ETS

    NSCLC non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  19. IMFINZI 50 mg/mL concentrate for solution for infusion.

    CERO THERAPEUTICS HOLDINGS, INC.

    oligometastatic hormone sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  20. IMFINZI 50 mg/mL concentrate for solution for infusion., Ampligen

    Disc Medicine

    Metastatic pancreatic cancer

    phase 2 small molecule active

    1 trial

  21. IMFINZI 50 mg/mL concentrate for solution for infusion., BEVACIZUMAB, IMJUDO 20 mg/ml concentrate for solution for infusion.

    AstraZeneca AB

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  22. IMFINZI 50 mg/mL concentrate for solution for infusion., CAPECITABINE , TREMELIMUMAB

    The George Institute

    Biliary tract cancer

    phase 2 small molecule active

    1 trial

  23. IMFINZI 50 mg/mL concentrate for solution for infusion., CARBOPLATIN , IMFINZI 50 mg/mL concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., PEMETREXED , PACLITAXEL , IMFINZI 50 mg/mL concentrate for solution for infusion., IPH5201, CISPLATIN

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer II, III

    phase 2 small molecule active

    1 trial

  24. IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN

    Ningbo Cancer Hospital

    Oropharyngeal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  25. IMFINZI 50 mg/mL concentrate for solution for infusion., Ceralasertib, Inflectra 100 mg powder for concentrate for solution for infusion, Mycophenolate Mofetil 250 mg Capsules

    AstraZeneca AB

    Unresectable or Advanced Melanoma

    phase 2 small molecule active

    1 trial

  26. IMFINZI 50 mg/mL concentrate for solution for infusion., FLUOROURACIL, FOLINIC ACID, OXALIPLATIN

    Ningbo Cancer Hospital

    Localised unresectable adenocarcinoma or squamous cell carcinoma of the oesophagus without any prior chemotherapy, surgery, or radiotherapy

    phase 2 small molecule active

    1 trial

  27. IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion.

    The George Institute

    Metastatic squamous cell carcinoma of head and neck, lung, esophagus, cervix, vagina, vulva or anus to be treated with SBRT

    phase 2 small molecule active

    1 trial

  28. IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion.

    AstraZeneca AB

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  29. IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion.

    Partner Therapeutics Limited

    NSCLC, synchronous oligo-metastatic

    phase 2 small molecule active

    1 trial

  30. IMFINZI 50 mg/mL concentrate for solution for infusion., INFLIXIMAB, Lynparza 100 mg film-coated tablets, MYCOPHENOLATE MOFETIL, Lynparza 150 mg film-coated tablets

    AstraZeneca AB

    BRCA Mutations and Early Stage HER2-Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  31. IMFINZI 50 mg/mL concentrate for solution for infusion., TREMELIMUMAB

    Pari Pharma GmbH

    Hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  32. IMFINZI 50 mg/mL concentrate for solution for infusion., TREMELIMUMAB

    The George Institute

    Intermediate stage hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  33. IMFINZI 50 mg/mL concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion

    Partner Therapeutics Limited

    Extensive-disease small cell lung cancer and high SLFN11-expression

    phase 2 small molecule active

    1 trial

  34. IMJUDO 20 mg/ml concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    Advanced stage intrahepatic biliary tract cancer (BTC)

    phase 2 small molecule active

    1 trial

  35. IMLIFIDASE

    The George Institute

    kidney trasplant

    phase 2 small molecule active

    1 trial

  36. IMMUNE RESET TO ALLOW ACCESS TO HLA-COMPATIBLE KIDNEY TRANSPLANTATION IN HYPERIMMUNIZED PATIENTS

    The George Institute

    chronic kidney disease, Hypersensitized patients

    phase 2 other active

    1 trial

  37. IMP1734

    Eikon Therapeutics

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  38. IMX-110 combined with Tislelizumab

    Immix Biopharma

    Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  39. IN10018

    Hospital Authority, Hong Kong

    Cervical Adenocarcinoma

    phase 2 small molecule active

    1 trial

  40. INAVOLISIB

    Fondazione Telethon ETS

    endometrial cancer

    phase 2 small molecule active

    1 trial

  41. INAVOLISIB, DOCETAXEL, INAVOLISIB, ENZALUTAMIDE, ENZALUTAMIDE, ABIRATERONE

    Hoffmann-La Roche

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  42. INAVOLISIB, FULVESTRANT, INAVOLISIB

    Hoffmann-La Roche

    Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA)-Mutated, hormone receptor-positive (HR-Positive), human epidermal growth factor receptor 2 (HER2)-Negative Locally Advanced or Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  43. INAVOLISIB, RIBOCICLIB, INAVOLISIB, RIBOCICLIB, Inavolisib placebo, FULVESTRANT

    Hoffmann-La Roche

    Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer with Chromosome 8p Loss and Without PIK3CA Mutation

    phase 2 small molecule active

    1 trial

  44. INAVOLISIB, RO 743-5846/F04, RO7223619, INAVOLISIB, RO 743-5846/F07, Ipatasertib, Rozlytrek 200 mg hard capsules, Alecensa 150 mg hard capsules, Rozlytrek 100 mg hard capsules, Tecentriq 1 200 mg concentrate for solution for infusion, INAVOLISIB, Rozlytrek, Ipatasertib, Camonsertib, INAVOLISIB, RO 749-9790/F02-02

    Hoffmann-La Roche

    Solid tumors

    phase 2 small molecule active

    1 trial

  45. INBRX-101 Concentrate for Solution for Infusion 50mg/ml

    Sanofi-aventis Healthcare Pty Ltd

    Alpha-1 Antitrypsin Deficiency (AATD) Emphysema

    phase 2 small molecule active

    1 trial

  46. INBRX-106 - Hexavalent OX40 agonist antibody

    Inhibrx Biosciences

    Solid Tumor

    phase 2 small molecule active

    1 trial

  47. INBRX-109

    Inhibrx Biosciences

    Conventional Chondrosarcoma

    phase 2 small molecule active

    1 trial

  48. INC280

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.